

Supplementary Information

American Journal of Cardiovascular Drugs

Strategy for an early simultaneous introduction of four-pillars of heart failure therapy: results from a single center experience

Paolo Severino^{1†*}, Andrea D'Amato^{1†}, Silvia Prosperi¹, Marco Valerio Mariani¹, Vincenzo Myftari¹, Aurora Labbro Francia¹, Claudia Cestìè¹, Elisa Tomarelli¹, Giovanna Manzi¹, Lucia Ilaria Birtolo¹, Stefanie Marek-Iannucci¹, Viviana Maestrini¹, Massimo Mancone¹, Roberto Badagliacca¹, Francesco Fedele¹, Carmine Dario Vizza¹.

¹ Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.

† These Authors contributed equally

* Corresponding Author: Email pao.lo.severino@uniroma1.it

Table S1. Baseline features of the total population and each group before the propensity score matching (PMS) analysis at hospital admission.

Parameter	Overall population (N=320)	Group 1 (N= 139)	Group 2 (N=181)	p-value
Age, years (SD)	71.3 (±10.9)	69.7 (±13.2)	73 (±11.7)	0.01
Male gender, n (%)	87 (27)	29 (20.9)	58 (32.3)	0.03
Arterial hypertension, n (%)	263 (82)	111 (79.9)	152 (84)	0.38
Type II diabetes mellitus, n (%)	60 (18.7)	22 (15.9)	38 (21)	0.25
Dyslipidemia, n (%)	160 (50)	58 (41.7)	102 (56.5)	0.013
CVD family history, n (%)	106 (33)	34 (24.5)	72 (40)	0.004
Smoking habit, n (%)	95 (30)	47 (33.8)	48 (26.7)	0.17
eGFR, ml/min (SD)	60.4 (±24.1)	62.2 (±24)	58.4 (±23.5)	0.15
LVEDD, mm (SD)	55.6 (±7.5)	58 (±4.2)	51.8 (±7.2)	< 0.001
IVS, mm (SD)	11.1 (±1.7)	11 (±1.1)	11.3 (±1.7)	0.07
PW, mm (SD)	10.2 (±1.2)	10 (±1.3)	10.5 (±1.4)	0.001
LVEF, % (SD)	33.1 (±10.2)	31.1 (±9.9)	35.3 (±12.7)	0.001

CVD cardiovascular disease, *eGFR* estimated glomerular filtration rate, *Hb* hemoglobin, *LVEDD* left ventricular end diastolic diameter, *IVS* interventricular septum, *PW* posterior wall, *LVEF* left ventricle ejection fraction, *NYHA* New York Heart Association.